Edgewise Therapeutics Inc (EWTX)
20.91
-0.32
(-1.51%)
USD |
NASDAQ |
May 08, 16:00
20.91
0.00 (0.00%)
After-Hours: 20:00
Edgewise Therapeutics Net Income (Quarterly): -30.14M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -30.14M |
September 30, 2023 | -25.71M |
June 30, 2023 | -21.47M |
March 31, 2023 | -22.84M |
December 31, 2022 | -19.42M |
September 30, 2022 | -17.50M |
June 30, 2022 | -16.07M |
March 31, 2022 | -14.66M |
Date | Value |
---|---|
December 31, 2021 | -12.70M |
September 30, 2021 | -12.95M |
June 30, 2021 | -10.35M |
March 31, 2021 | -6.815M |
December 31, 2020 | -6.342M |
September 30, 2020 | -3.642M |
June 30, 2020 | -3.954M |
March 31, 2020 | -3.185M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-30.14M
Minimum
Dec 2023
-3.185M
Maximum
Mar 2020
-14.23M
Average
-13.80M
Median
Net Income (Quarterly) Benchmarks
Sarepta Therapeutics Inc | 36.12M |
PTC Therapeutics Inc | -91.58M |
Fate Therapeutics Inc | -44.12M |
Viking Therapeutics Inc | -27.36M |
Regenxbio Inc | -62.89M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 33.86M |
EPS Diluted (Quarterly) | -0.47 |
Enterprise Value | 1.658B |
Earnings Yield | -7.56% |